Jacobson Pharma Corporation Limited 2633

The Swiss drugmaker will pay $575 million upfront to license ABO2203, with up to $7.2 billion more tied to milestones

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:OCTOPUS INVESTMENTS LTD(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree i

Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation Presentations on CLYM116 and budoprutug programs highlight advancements across the portfolio WELLESLEY HILLS, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for its CLYM116 and b

BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, from October 22 to 25. The final efficacy analysis of the ORIGIN 3 trial of TRUTAKNA in IgA nephropathy (IgAN) will be a featured late-breaking oral presentation during the opening plenary session and also a late-breaking rese

Global bond markets have just steadied after a sharp sell off that pushed US borrowing costs to levels last seen in 2002, which keeps reliable cash generation and robust finances firmly in focus. That backdrop puts financially solid healthcare leaders, from drug developers to equipment makers, on many watchlists. This article walks through three stand out stocks from a curated healthcare shortlist that meet those quality filters. The three healthcare stocks highlighted next are only a...

Johnson & Johnson (JNJ) is back in focus after new IMAAVY data in generalized myasthenia gravis, giving investors fresh insight into how its immunology pipeline might complement the stock’s recent double digit one year return. Despite the IMAAVY update and a string of recent drug data releases across immunology, oncology and neuroscience, Johnson & Johnson’s share price has eased in the short term, with the stock down 4.4% over the past week and 4.6% over the past month. However, a 24.8% year...

Immunome, Inc. recently reported that the FDA cleared its Investigational New Drug application for IM-1340, a potential first-in-class antibody-drug conjugate for advanced solid tumors, enabling the company to begin a Phase 1 trial focused on safety, tolerability, pharmacokinetics, and early anti-tumor activity. By pairing a transport receptor broadly expressed across solid tumors with its proprietary HC74 topoisomerase I inhibitor payload, Immunome is adding another differentiated oncology...

In September 2026, OptimizeRx Corp. announced it had integrated its authenticated point of care inventory with The Trade Desk’s OpenPath, giving advertisers direct programmatic access via The Trade Desk’s demand side platform to a proprietary healthcare network spanning more than 400 EHR and e-prescribe systems and 800,000 verified healthcare professionals. This move deepens The Trade Desk’s healthcare-focused inventory and could make its platform more attractive to life sciences advertisers...

The fair value estimate for Aurobindo Pharma has been nudged higher to ₹1,713.74 from ₹1,678.32, which provides an updated anchor for thinking about the stock’s pricing. Analysts link this change to a balance of optimism about earnings quality and caution regarding how consistently the company can execute its plans. As you read on, you will see how this refreshed valuation fits into the broader analyst narrative and how to track future shifts in sentiment around Aurobindo Pharma. Analyst...

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the European Academy of Dermatology and Venereology (EADV) Annual Meeting, being held in Vienna, Austria, from September 30 through October 3, 2026.

Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc) treated with AlloNK plus rituximab in the ongoing Phase 2a basket trial, all with at least six months of follow-upPoster presentation highlighting deep, consistent B-cell depletion comparable to that observed with CD19 CAR T-cell therapies and a favorable tolerability profile acros

CAMBRIDGE, Mass., October 02, 2026--Obsidian Therapeutics, Inc. ("Obsidian") (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced a poster presentation of updated data in patients with immune-checkpoint inhibitor (ICI)-resistant advanced melanoma from the Phase 1 single-center first-in-human (FIH) study and the Phase 1/2 Agni-01 multicenter study of amsoki

Santhera Pharmaceuticals CFO Catherine Isted joined Steve Darling from Proactive to discuss the company’s financial results for the six months ended June 30, 2026, highlighting strong commercial momentum for AGAMREE® and significant progress in expanding patient access across international markets. Santhera reported total revenue of CHF 48.3 million for the first half of 2026, representing a 101% increase from CHF 24.0 million during the same period in 2025. The growth was driven by a combination of higher AGAMREE® product sales and increased royalties and milestone income, including proceeds

Eli Lilly just posted a 47.7% revenue surge while rivals like Novo Nordisk are watching earnings fall, and a fresh pipeline catalyst could push Lilly toward a valuation Wall Street has only seen from two companies in history.

agenT-797 enables tumor-cell killing in a human relevant model of checkpoint inhibitor–resistant colorectal cancer liver metastasesNative and engineered iNKT cells eliminate senescent tumor cells and fibroblasts in preclinical models, supporting complementary approaches to cancer treatment NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to res

Acquiring 100% of East Coast Podiatry (five clinics) and Orchard Clinic (two clinics) for approximately S$4.0 million (approximately US$3.1 million)Target Group generated FY2025 unaudited revenue of approximately S$9.1 million and unaudited normalized EBITDA of approximately S$1.2 million, based on unaudited management accountsSellers’ consideration shares subject to a lock-upAdds an established clinical platform directly aligned with Cuprina’s wound-care and collagen technologies SINGAPORE, Oct